<SEC-DOCUMENT>0001279569-17-000203.txt : 20170210
<SEC-HEADER>0001279569-17-000203.hdr.sgml : 20170210
<ACCEPTANCE-DATETIME>20170210085437
ACCESSION NUMBER:		0001279569-17-000203
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170210
FILED AS OF DATE:		20170210
DATE AS OF CHANGE:		20170210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		17589774

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of February 2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">News Release dated February 10, 2017 - ESSA Pharma to Present at 2017 BIO CEO &amp; Investor Conference</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
     February 10, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED FEBRUARY 10, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><IMG SRC="image_001.jpg" ALT="https:||mma.prnewswire.com|media|466889|ESSA_Pharma_Inc_Essa_Pharma_to_Present_at_2017_BIO_CEO___Investo.jpg" STYLE="height: 154px; width: 400px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA Pharma to Present at 2017 BIO CEO &amp; Investor
Conference</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, Feb. 10, 2017 /CNW/ - ESSA Pharma Inc.
(TSX: EPI, NASDAQ: EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;) a clinical stage company focused on the development of small
molecule drugs for the treatment of cancer, today announced that David R. Parkinson, President and Chief Executive Officer will
be presenting at the 2017 BIO CEO &amp; Investor Conference in New York City on Tuesday, February 14<SUP>th</SUP> at 1:00pm Eastern
Time at the Waldorf Astoria New York.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Dr. Parkinson will provide a corporate overview of the Company's
business and will be available for one-on-one meetings during the conference.&nbsp;ESSA's Chief Financial Officer, David S. Wood
and ESSA's Chief Operating Officer, Peter Virsik, will be also in attendance.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer</B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease (mCRPC) and most patients ultimately succumb to the illness. The treatment
of mCRPC patients has evolved rapidly over the past five years; despite these advances, additional treatment options are needed
to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those that have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about the Company's upcoming Phase
1/2 clinical trial; expectations regarding the initiation of the Phase 2 dose expansion study; receipt of additional CPRIT funds;
and</I>&nbsp;<I>the implementation of the Company's business model and strategic plans.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
obtaining positive results of clinical trials; (ii) obtaining regulatory approvals; and (iii) general business, market and economic
conditions.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's</I>&nbsp;<I>Annual Report on Form 20-F dated December
14, 2016 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">To view this news release in HTML formatting, please use the
following URL: http://www.newswire.ca/en/releases/archive/February2017/10/c6083.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962; Peter Virsik, Executive Vice President &amp; Chief Operating Officer, Tel: (832) 831-5958</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 08:30e 10-FEB-17</P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  0" P,# @0# P,$! 0$!0D&!04%
M!0L(" 8)#0L-#0T+# P.$!01#@\3#PP,$A@2$Q46%Q<7#A$9&QD6&A06%Q;_
MVP!# 00$! 4%!0H&!@H6#PP/%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86%A;_P  1" ": 9 # 2(  A$! Q$!_\0
M'0 !  ,  P$! 0            <("00%!@(! __$ %80  $# P("!@()#@L%
M"0    $  @,$!08'$1(A"!,Q46%Q(D$)%!48,H&"D94C-T)2559R=9*4L]'2
MTQ87)#A#5&*#DZ&Q)28SLL$T-4578W2BH[3_Q  < 0$  @,! 0$
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MW)KAOP05+3(W\)A(<WR("]#OY_,LF02'AXY.'8X=H^-<T7F\"+JA=J\1[;<
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M!'8PP.#K2-)-SH;ZW7Z,R;F5N7Y',<SI1. ! U'1T(W;]-G%44:"2  22=@
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6$1$1$1$1$1$1$1$1$1$1$1$1$7__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
